Last reviewed · How we verify

BMS-663068 — Competitive Intelligence Brief

BMS-663068 (BMS-663068) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV attachment inhibitor. Area: Infectious Disease / Virology.

phase 3 HIV attachment inhibitor HIV gp120 envelope protein / CD4 receptor interaction Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

BMS-663068 (BMS-663068) — ViiV Healthcare. BMS-663068 is an HIV attachment inhibitor that blocks the interaction between HIV and the CD4 receptor on host cells, preventing viral entry.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
BMS-663068 TARGET BMS-663068 ViiV Healthcare phase 3 HIV attachment inhibitor HIV gp120 envelope protein / CD4 receptor interaction

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV attachment inhibitor class)

  1. ViiV Healthcare · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BMS-663068 — Competitive Intelligence Brief. https://druglandscape.com/ci/bms-663068. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: